{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Blood samples were planned to be collected from participants in the pharmacokinetic/pharmacodynamic expansion cohort for analysis of GSK2816126 and its metabolites. Samples were not collected due to early termination of the study; therefore, no analysis could be performed.","groups":[{"description":"At maximum tolerated or recommended phase II dose, participants with GCB-DLBCL were enrolled in Part 1 expansion cohorts and received GSK2816126 twice-weekly, as intravenous solution.","id":"OG000","title":"Part 1: Participants With GCB-DLBCL"},{"description":"At maximum tolerated or recommended phase II dose, participants with solid tumors were enrolled in Part 1 expansion cohorts and received GSK2816126 twice-weekly, as intravenous solution.","id":"OG001","title":"Part 1: Participants With Solid Tumors"}],"populationDescription":"Pharmacokinetic Population. Samples were not collected due to early study termination.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, (12, 18 on Day 1 only), 24, and 96 hours post-dose from start of infusion; 0.5, 1, 2, 4, 6 hours from end of infusion on Cycle 1 of Day 1 and Day 15 (Each cycle was of 28 days)","title":"Part 1: Concentration of GSK2816126 and Its Metabolites in Blood","type":"SECONDARY"}